CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


CK0802Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug597 Cognitive Training Wiki 1.00
drug2564 Trivia Training Wiki 1.00
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D001008 Anxiety Disorders NIH 0.17

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Phase 1 Double-Blinded, Randomized, Placebo Controlled Safety and Early Efficacy Trial of Cryopreserved Cord Blood Derived T-Regulatory Cell Infusions (CK0802) In The Treatment Of COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS)

To assess the safety and efficacy of CK0802 in treatment of patients with COVID-19 induced moderate-to-severe PNA-ARDS.

NCT04468971 COVID19 ARDS Biological: CK0802 Drug: Placebo

Primary Outcomes

Description: Regimen related ≥ grade 3 toxicity within 48 hours of first infusion (DLT)

Measure: Regimen related ≥ grade 3 toxicity within 48 hours of first infusion

Time: 48 hours

Description: Alive and not intubated 28 days after the date of first infusion

Measure: 28-day treatment success, defined as S28

Time: 28 days

Secondary Outcomes

Description: Time to extubation

Measure: Time to extubation

Time: 28 days

Description: Oxygenation requirement (PaO2/FiO2) change between day 0 and day +11

Measure: Oxygenation improvement

Time: 11 days

Description: Ventilator free days measured at day 28

Measure: Ventilator free days

Time: 28 days

Description: Organ failure free days measured at day 28

Measure: Organ failure free days

Time: 28 days

Description: ICU free days measured at day 28

Measure: ICU free days

Time: 28 days

Description: All-cause mortality at day 28

Measure: All-cause mortality

Time: 28 days


No related HPO nodes (Using clinical trials)